Effects of intravenous human albumin, enteral cilostazol, and combination therapy on the reduction of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage - Takeaways - MDSpire

Effects of intravenous human albumin, enteral cilostazol, and combination therapy on the reduction of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage

  • By

  • Adnan I. Qureshi

  • Hassan Raza

  • Jonathan Beall

  • Byron Gajewski

  • Renee H. Martin

  • Jose I. Suarez

  • July 16, 2026

Share

  • 1

    Delayed cerebral ischemia (DCI) and cerebral infarction are significant causes of disability and death after aneurysmal subarachnoid hemorrhage (aSAH).

  • 2

    The study estimated the effects of intravenous human albumin, enteral cilostazol, and their combination on reducing DCI using Bayesian prior-predictive simulation.

  • 3

    Median absolute risk reductions for DCI were 9.1% for albumin, 18.1% for cilostazol, and 21.7% for combination therapy compared to control.

  • 4

    The incremental benefit of adding albumin to cilostazol was small and uncertain, with an estimated increase of only 3.5 percentage points.

  • 5

    The findings suggest the need for continued randomized evaluation of cilostazol and albumin to estimate their effects on DCI.

Original Source(s)

Effects of intravenous human albumin, enteral cilostazol, and combination therapy on the reduction of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage

  • by Adnan I. Qureshi, Hassan Raza, Jonathan Beall, Byron Gajewski, Renee H. Martin, Jose I. Suarez

  • July 16, 2026

Related Content

Feasibility and preliminary signal of cerebellar intermittent theta burst stimulation for static balance in cerebellar ataxia: a pilot study

Altered EEG microstate dynamics in adolescents with non-suicidal self-injury at rest and following acute social exclusion

MSPEECH (multiple sclerosis monitoring through speech interaction in clinic and at home): a Living Lab study protocol for co-created, speech-based digital biomarkers in multiple sclerosis